Format
Sort by

Send to

Choose Destination

Selected items

Items: 5

1.

Roles of conformational and positional adaptability in structure-based design of TMC125-R165335 (etravirine) and related non-nucleoside reverse transcriptase inhibitors that are highly potent and effective against wild-type and drug-resistant HIV-1 variants.

Das K, Clark AD Jr, Lewi PJ, Heeres J, De Jonge MR, Koymans LM, Vinkers HM, Daeyaert F, Ludovici DW, Kukla MJ, De Corte B, Kavash RW, Ho CY, Ye H, Lichtenstein MA, Andries K, Pauwels R, De B├ęthune MP, Boyer PL, Clark P, Hughes SH, Janssen PA, Arnold E.

J Med Chem. 2004 May 6;47(10):2550-60.

PMID:
15115397
2.

Crystal structures of clinically relevant Lys103Asn/Tyr181Cys double mutant HIV-1 reverse transcriptase in complexes with ATP and non-nucleoside inhibitor HBY 097.

Das K, Sarafianos SG, Clark AD Jr, Boyer PL, Hughes SH, Arnold E.

J Mol Biol. 2007 Jan 5;365(1):77-89. Epub 2006 Sep 15.

PMID:
17056061
3.

High-resolution structures of HIV-1 reverse transcriptase/TMC278 complexes: strategic flexibility explains potency against resistance mutations.

Das K, Bauman JD, Clark AD Jr, Frenkel YV, Lewi PJ, Shatkin AJ, Hughes SH, Arnold E.

Proc Natl Acad Sci U S A. 2008 Feb 5;105(5):1466-71. doi: 10.1073/pnas.0711209105. Epub 2008 Jan 29.

4.

Crystal engineering of HIV-1 reverse transcriptase for structure-based drug design.

Bauman JD, Das K, Ho WC, Baweja M, Himmel DM, Clark AD Jr, Oren DA, Boyer PL, Hughes SH, Shatkin AJ, Arnold E.

Nucleic Acids Res. 2008 Sep;36(15):5083-92. doi: 10.1093/nar/gkn464. Epub 2008 Aug 1.

5.

HIV-1 reverse transcriptase complex with DNA and nevirapine reveals non-nucleoside inhibition mechanism.

Das K, Martinez SE, Bauman JD, Arnold E.

Nat Struct Mol Biol. 2012 Jan 22;19(2):253-9. doi: 10.1038/nsmb.2223.

Supplemental Content

Write to the Help Desk